Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ten Months On, Abbott, Wockhardt Terminate Deal For Nutritional Business

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Pharmaceuticals-to-diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt jointly agreed to call off the $130 million deal for a nutritional business that the two had announced barely 10 months ago

You may also be interested in...



INTERVIEW: Abbott Nutrition Revs Up For Bigger India Play

A combination of factors is aiding Abbott Nutrition’s pitch for a bigger slice of the evolving Indian nutrition market. The company is already growing at a rate far higher than the industry average of 12%, a pace it expects to maintain for the next few years.

INTERVIEW: Abbott Nutrition Revs Up For Bigger India Play

A combination of factors is aiding Abbott Nutrition’s pitch for a bigger slice of the evolving Indian nutrition market. The company is already growing at a rate far higher than the industry average of 12%, a pace it expects to maintain for the next few years.

Danone Gets Second Time Lucky, Buys Wockhardt's Nutrition Brands That Abbott Had Won And Lost

HYDERABAD, India - After several months of discussions, debt-laden Indian drug maker Wockhardt Ltd. finally managed to sell its growing nutritional business to French food giant Group Danone for reportedly $354 million - a quantum jump from the $130 million that Abbott Laboratories Ltd. had agreed to pay for the same assets exactly two years ago

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel